Coegin Pharma AB announced that its CEO Jens Eriksson, CFO Lars Bukhave Rasmussen, and CMO John Zibert have acquired additional shares in the company, totaling 87,477 shares. Jens Eriksson acquired 24,293 shares, Lars Bukhave Rasmussen acquired 26,300 shares, and John Zibert acquired 36,884 shares. Post-acquisition, Jens Eriksson holds 503,497 shares, Lars Bukhave Rasmussen holds 95,295 shares, and John Zibert holds 96,295 shares. The transactions were carried out on Nordic SME. Coegin Pharma, based in Lund, Sweden, is a biotech company focused on innovations for hair and skin, with products like Follicopeptide® and NPP-4. The company's shares are listed on NGM Nordic SME and Börse Stuttgart. More information can be found on their website.

Coegin Pharma AB has received its first purchase order for a new cosmetic scalp serum from its Follicopeptide® portfolio, placed by its commercial partner Gents. This order marks an initial commercial step in expanding Coegin's product offerings and market reach. The scalp serum is designed as both a stand-alone hair product and a part of the Follicopeptide portfolio, enhancing the user experience. Production is outsourced to a Danish partner, allowing Coegin to focus on scaling its in-house production of other products. Coegin's CEO, Jens Eriksson, highlights the order as a sign of strong partner interest, while Gents' CEO, Jenny Rydhström, expresses enthusiasm about adding the product to their premium grooming portfolio. This development is part of Coegin's shift towards a commercially driven innovation company in hair and skin care. Coegin Pharma is a Swedish biotech firm known for its innovations in hair and skin, commercializing its patented Follicopeptide® globally and developing new skin pigmentation regulation technology.

Coegin Pharma AB has announced the launch of a new cosmetic scalp serum that enhances its Follicopeptide product line. This product aims to improve the scalp environment and can be used both independently and as part of the Follicopeptide portfolio. The serum is expected to increase market penetration, strengthen partnerships, and boost long-term revenue potential while maintaining operational efficiency. The product will be manufactured in Denmark and is set for launch in Q2 2026. Coegin has received interest from existing and potential partners, and the launch is part of a strategy to expand their product ecosystem and commercial reach. Coegin Pharma is a Swedish biotech company known for its hair and skin innovations, with its shares listed on NGM Nordic SME and Börse Stuttgart.

Coegin Pharma AB's Board of Directors has decided to execute directed issues amounting to approximately SEK 12.1 million, involving the issuance of up to 3,713,750 shares and 1,856,875 warrants of series 2026/2027. Of this, SEK 5.1 million will be used for loan set-offs and SEK 7 million for cash proceeds. The issues, aimed at strengthening liquidity and supporting the commercial expansion of Follicopeptide®, are directed at shareholders Alveco Invest AB, Bengt Svenstig, Lennart Börjesson, and Crystallus AB, with shares priced at SEK 3.25 each, reflecting a 15% discount on the recent average share price. The warrants are issued without charge. The initiative aims to improve cash flow, reduce reliance on external financing, and support international expansion. The Board chose this approach over a rights issue due to time and cost efficiency. The issues are expected to dilute the company's shares by approximately 7.97% and 5.46% for the directed cash and set-off issues, respectively, with a potential further 6.10% dilution if all warrants are exercised. Coegin Pharma is a Swedish biotech firm focused on hair and skin innovations, currently expanding its Follicopeptide® product globally.

Coegin Pharma AB has successfully completed the start-up of commercial production for its product Follicopeptide, ensuring stable supply through adapted batch sizes and quality controls. Deliveries to existing partners Gents and Hårklinikken are proceeding as planned, with production aligned with demand forecasts. The company is gradually scaling up production capacity starting January 2026. A complementary product has been developed and will soon be offered to partners, with production secured internally and externally. Coegin continues to develop additional Follicopeptide-based products and is actively seeking more distributors for international expansion in 2026. The development of the skin pigmentation peptide NPP-4 will intensify, targeting a market launch by late 2026. Coegin is preparing a financial plan for 2026 to achieve balanced cash flow and maximize shareholder value. CEO Jens Eriksson expressed confidence in the company's growth and long-term value creation as they enter 2026. Coegin Pharma, a Swedish biotech company, specializes in hair and skin innovations and is listed on NGM Nordic SME and Börse Stuttgart. More information is available on their website.

Coegin Pharma AB has appointed Professor Desmond J. Tobin, a prominent expert in skin and hair pigmentation science, as a Scientific Advisor. Prof. Tobin, a co-inventor of Coegin's skin pigmentation peptide NPP-4, has extensive research experience in melanocyte and hair-follicle biology, contributing significantly to the understanding of these fields. He will advise Coegin on their skin-pigmentation peptide NPP-4 and hair-growth assets. Additionally, Professors Anna Hultgårdh Nilsson and Jan Nilsson from Lund University, both key figures in Coegin's peptide platform, serve as strategic advisors. Coegin Pharma, a Swedish biotech company, focuses on innovations for hair and skin, including the commercialized hair growth product Follicopeptide®. The company is listed on NGM Nordic SME and Börse Stuttgart and is based in Lund, Sweden.

Coegin Pharma AB has completed its first commercial delivery of hair growth products based on Follicopeptide® to Hårklinikken, an international provider of specialized hair and scalp treatments. This delivery is a significant step in Coegin's commercial expansion, following a similar delivery to Gents. The partnership with Hårklinikken enhances Coegin's presence in the professional segment, where products are introduced through experts and clinics. The successful delivery demonstrates Coegin's capability to supply multiple commercial partners and aligns with professional market standards. CEO Jens Eriksson views this as a milestone and an endorsement of Coegin's science. The company continues to work with partners to establish Follicopeptide as a leading solution in premium and professional hair growth markets. Coegin Pharma, a Swedish biotech company, is known for its innovations in hair and skin, and is listed on NGM Nordic SME and Börse Stuttgart.

Coegin Pharma AB has announced the successful production and delivery of its first commercial batch of hair growth products based on Follicopeptide® to Gents, a leading Nordic grooming retailer. The pre-order batch sold out rapidly, highlighting strong consumer interest before the full market launch planned for January 2026. This milestone marks Coegin's transition from development to commercial operations, with CEO Jens Eriksson noting the validation of their product and strategy. Coegin plans further deliveries, including to Hårklinikken, strengthening its presence in premium distribution channels. The company aims to establish Follicopeptide as a leading solution in the premium hair growth market. Coegin Pharma is a Swedish biotech company focused on hair and skin innovations, currently commercializing Follicopeptide® globally and developing a new peptide for skin pigmentation regulation. Coegin is listed on NGM Nordic SME and Börse Stuttgart, with headquarters in Lund, Sweden.

The Nomination Committee for Coegin Pharma's 2026 Annual General Meeting has been appointed following the guidelines set at the 2025 Annual General Meeting. The committee members are Johan Arver (Chair), Martin Tisell, Rune Löderup, and Eva Sjökvist Saers. Their responsibilities include preparing proposals for the meeting regarding various roles and fees, as well as potential changes to the committee's guidelines. The meeting is scheduled for May 21, 2026, in Lund, Sweden. Shareholders can submit proposals by January 15, 2026, via email. The committee's proposals will be available in the meeting notice and on the company's website. Coegin Pharma, a Swedish biotech company, focuses on hair and skin innovations and is listed on NGM Nordic SME and Börse Stuttgart. More information is available on their website.

Coegin Pharma AB has announced that starting November 16, customers can pre-order the Gents Power Hair Activating Formula, marking a significant commercial milestone as the first Follicopeptide-based consumer product becomes available for purchase. Deliveries are expected to begin in December 2025. The product, developed in collaboration with Swedish retailer Gents, aims to enhance hair density and improve scalp health. Coegin's CEO, Jens Eriksson, expressed pride in reaching this milestone, emphasizing the transition from research to consumer availability. Gents' CEO, Jenny Rydhström, highlighted the excitement surrounding the product, noting its scientific basis in hair care. This launch is part of Coegin's strategy to globally commercialize its Follicopeptide-based innovations, showcasing its ability to move from development to market. Coegin Pharma is a Swedish biotech company focused on hair and skin innovations, with its shares listed on NGM Nordic SME and Börse Stuttgart. Gents is a Swedish retailer specializing in premium men's grooming products.

Coegin Pharma AB has announced the completion of a new complementary product for its Follicopeptide line, aimed at strengthening hair and enhancing product performance. This add-on, expected to launch by March 2026, is part of Coegin's strategy to expand its Follicopeptide ecosystem commercially. The product is designed to improve scalp receptiveness and user experience, offering potential for increased profitability and brand loyalty. Positive feedback has been received from partners, indicating commercial interest. Coegin Pharma is a Swedish biotech company known for innovations in hair and skin care, with its shares listed on NGM Nordic SME and Börse Stuttgart.

Coegin Pharma AB has partnered with Hårklinikken, a global leader in hair and scalp health, through a non-exclusive limited purchase order to commercialize Coegin's hair growth innovation, Follicopeptide®. This collaboration aims to introduce the product to a premium international audience by leveraging Hårklinikken's extensive clinical experience and global presence. Hårklinikken will launch the first Follicopeptide-based product under its label in early 2026, aligning with Coegin's strategy for accelerated market entry. Management from both companies expressed optimism about the partnership, highlighting the synergy between Coegin's scientific innovation and Hårklinikken's reputation and customer reach. Coegin Pharma, a Swedish biotech company, focuses on hair and skin innovations and is listed on NGM Nordic SME and Börse Stuttgart. Hårklinikken, with over 33 years of research, is known for its customized treatments and global clinics.